Key contacts

Will Corkill

Will Corkill

Simon Wilson

Simon Wilson

Regional office - Australia
Level 25
Aurora Place
88 Phillip Street
NSW 2000
Tel: +61 (0)2 9258 1161

Regional office - New Zealand
Level 15
171 Featherston Street
Wellington 6011
New Zealand
Tel: +64 (0)4 8948555

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Greka Drilling Bezant Resources
Green Dragon Gas Baobab Resources
Endace Wynnstay Group
PXP Vietnam Fund Chatham Rock Phosphate
Tenon MMG
SeaDragon Contact Energy
Cue Energy New Zealand Oil & Gas
Rubicon Sky Network Television
Sealegs Corporation Kreuz Holdings
See more

Latest research

Galaxy Resources

Cash flow generation at Mt Cattlin

Outlook | Mining | 17/10/2016

Galaxy Resources (GXY) has exposure to both hard rock lithium assets (Mt Cattlin, James Bay) and brine-based lithium assets (Sal de Vida). After the takeover of General Mining (GMM), Galaxy now has 100% of these assets. The Mt Cattlin project will begin shipments during December 2016, after its reopening, capitalising on current high lithium prices.


Termination of coverage

Update | Pharmaceutical & healthcare | 21/09/2016

Edison Investment Research is terminating coverage on Imugene (IMU). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.


Tightening focus to extend runway

Update | Pharmaceutical & healthcare | 21/09/2016

Mesoblast cut its cash burn by 15% in FY16 to US$90m, and guided for a further ~25% reduction in FY17, which will give it headroom to fund the Phase III heart failure (HF) trial that Teva relinquished in June. It has ~12 months of cash runway plus a US$90m equity finance facility, which will give a further 12 months’ runway. It expects to report interim analyses of three Phase III programmes by end Q117, including the HF trial. We lower our valuation ahead of these potential catalysts to A$1.5bn…


Japan licence deal close to finalisation

Update | Pharmaceutical & healthcare | 14/09/2016

Regeneus anticipates entering a binding arrangement with a manufacturing and commercialisation partner for its Progenza mesenchymal stem cell therapy technology in Japan by the end of the current quarter. Following on from the positive safety review of its STEP Phase I trial of Progenza in patients with knee osteoarthritis, it has already begun procuring donor material in preparation for manufacturing Progenza for a Phase II trial in Japan. Our valuation is virtually unchanged at A$108m (A$0.52/share)…


Funded until cash positive in FY17

Update | Technology | 07/09/2016

migme (MIG) is a global social media company employing a freemium model to drive user engagement. It is focused on the emerging markets of Indonesia, the Philippines and India. At 30 June 2016 monthly active users (MAUs) totalled 43 million, an increase of 34% in the last year (32 million in December 2015) and number of artists and verified users increased to 2,900 up 368% since 31 December 2015). On 19 August 2016 MIG raised A$10.2m from an issue of shares at A$0.40/share.


Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports See more sector reports